Investor Relations

Data Provided by Refinitiv. Minimum 15 minutes delayed.

 

 

Data Provided by Refinitiv. Minimum 15 minutes delayed.

 

 

Press Releases
23-Oct-20

First patient dosed in monalizumab Phase 3 clinical trial triggers $50M payment from AstraZeneca

Milestone payment further bolsters Innate’s cash position   INTERLINK-1 represents first Phase 3 study examining IO approach in R/M SCCHN patients who have been treated with a platinum-based therapy and PD-(L)1 inhibitor Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA)

13-Oct-20

Number of Shares and Voting Rights of Innate Pharma as of October 1, 2020

Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company

8-Sep-20

Innate Pharma reports first half 2020 financial results and business update

Innate resumed enrollment of lacutamab TELLOMAK Phase 2 clinical trial for patients with Sézary syndrome and mycosis fungoides Monalizumab Phase 3 study expected to initiate in the second half of 2020, triggering $50 million milestone payment Innate to explore avdoralimab in inflammation beyond